{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T04:16:16Z","timestamp":1783052176263,"version":"3.54.6"},"reference-count":63,"publisher":"Instituto Nacional de Salud (Colombia)","issue":"2","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100015274","name":"Ministerio de Salud","doi-asserted-by":"publisher","award":["OT-033-18"],"award-info":[{"award-number":["OT-033-18"]}],"id":[{"id":"10.13039\/501100015274","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["revistabiomedica.org"],"crossmark-restriction":false},"short-container-title":["Biomed."],"abstract":"<jats:p>Introducci\u00f3n. Se desconocen los factores que afectan la diversidad gen\u00e9tica y las mutaciones de resistencia al tratamiento antirretroviral del virus de la inmunodeficiencia humana en personal militar.Objetivo. Describir los factores que afectan la variabilidad gen\u00e9tica y la resistencia a los antirretrovirales del virus de la inmunodeficiencia humana en poblaci\u00f3n militar durante un a\u00f1o de seguimiento.Materiales y m\u00e9todos. Se incluyeron 52 militares peruanos infectados con el virus de la inmunodeficiencia humana y con terapia antirretroviral. Luego, se compar\u00f3 la diversidad gen\u00e9tica, los subtipos gen\u00e9ticos, los eventos de recombinaci\u00f3n y el perfil de resistencia que ocurrieron en los genes de la proteasa y la transcriptasa inversa durante 12 y 18 meses de seguimiento, considerando las caracter\u00edsticas socio-epidemiol\u00f3gicas de los participantes.Resultados. Se observ\u00f3 uso intermitente del preservativo (37 %), contacto con trabajadoras sexuales (17 %) y antecedentes de infecciones de transmisi\u00f3n sexual (56 %). La tasa de diversidad gen\u00e9tica (\u03c0) se elev\u00f3 de 0,30 a 0,45, mientras que los subtipos gen\u00e9ticos y formas recombinantes no cambiaron significativamente. De 11 muestras que evidenciaron cambios significativos de nucle\u00f3tidos, 5 presentaron mutaciones de resistencia. Finalmente, el an\u00e1lisis bivariado demostr\u00f3 que a mayor edad de los sujetos, mayor asociaci\u00f3n significativa con una diferencia del perfil de resistencia despu\u00e9s de un intervalo de 12 meses o m\u00e1s.Conclusi\u00f3n. Se demuestra que despu\u00e9s de 12 y 18 meses de seguimiento, el virus de la inmunodeficiencia humana que infecta un grupo de personal militar peruano sufri\u00f3 cambios de su diversidad gen\u00e9tica y de perfil de resistencia, los cuales se asociaron con la edad de los participantes.<\/jats:p>","DOI":"10.7705\/biomedica.7970","type":"journal-article","created":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T17:11:52Z","timestamp":1782321112000},"page":"303-323","update-policy":"https:\/\/doi.org\/10.7705\/crossmark","source":"Crossref","is-referenced-by-count":0,"title":["Diversidad gen\u00e9tica y resistencia antirretroviral del virus de la inmunodeficiencia humana de tipo 1 en personal militar peruano a los 12 y a los 18 meses de seguimiento","Genetic diversity and antiretroviral resistance of human immunodeficiency virus type 1 in Peruvian military personnel during one year of follow-up"],"prefix":"10.7705","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-6028-3304","authenticated-orcid":false,"given":"Jonathan","family":"Guerrero","sequence":"first","affiliation":[{"name":"Laboratorio de Biomedicina y Microbiolog\u00eda, Instituto Nacional de Salud, Lima, Per\u00fa"},{"name":"Laboratorio de Biomedicina y Microbiolog\u00eda, Instituto Nacional de Salud, Lima, Per\u00fa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4440-1765","authenticated-orcid":false,"given":"Dilan","family":"Su\u00e1rez","sequence":"additional","affiliation":[{"name":"Laboratorio de Virus de Transmisi\u00f3n Sexual, Unidad de Virolog\u00eda, Instituto Nacional de Salud, Lima, Per\u00fa"},{"name":"Laboratorio de Virus de Transmisi\u00f3n Sexual, Unidad de Virolog\u00eda, Instituto Nacional de Salud, Lima, Per\u00fa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9607-5693","authenticated-orcid":false,"given":"Carlos Augusto","family":"Yabar","sequence":"additional","affiliation":[{"name":"Laboratorio de Virus de Transmisi\u00f3n Sexual, Unidad de Virolog\u00eda, Instituto Nacional de Salud, Lima, Per\u00fa; Facultad de Medicina Humana, Universidad de San Mart\u00edn de Porres, Lima, Per\u00fa"},{"name":"Laboratorio de Virus de Transmisi\u00f3n Sexual, Unidad de Virolog\u00eda, Instituto Nacional de Salud, Lima, Per\u00fa; Facultad de Medicina Humana, Universidad de San Mart\u00edn de Porres, Lima, Per\u00fa"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4444","published-online":{"date-parts":[[2026,6,1]]},"reference":[{"key":"165051","unstructured":"World Health Organization. HIV and AIDS: key facts. Geneva: WHO; 2024. Fecha de consulta: 26 de noviembre del 2025. Disponible en: https:\/\/www.who.int\/news-room\/factsheets\/detail\/hiv-aids"},{"key":"165052","doi-asserted-by":"crossref","unstructured":"Oguntibeju OO. Quality of life of people living with HIV and AIDS and antiretroviral therapy. HIVAIDS Auckl NZ. 2012;4:117-24. https:\/\/doi.org\/10.2147\/HIV.S32321","DOI":"10.2147\/HIV.S32321"},{"key":"165053","doi-asserted-by":"crossref","unstructured":"Zhao Y, Wu Z, McGoogan JM, Shi CX, Li A, Dou Z, et al. Immediate antiretroviral therapy decreases mortality among patients with high CD4 counts in China: A nationwide, retrospective cohort study. Clin Infect Dis. 2018;66:727-34. https:\/\/doi.org\/10.1093\/cid\/cix878","DOI":"10.1093\/cid\/cix878"},{"key":"165054","doi-asserted-by":"crossref","unstructured":"Pennings PS. HIV drug resistance: problems and perspectives. Infect Dis Rep. 2013;5(Suppl 1):e5. https:\/\/doi.org\/10.4081\/idr.2013.s1.e5","DOI":"10.4081\/idr.2013.s1.e5"},{"key":"165055","unstructured":"Centro Nacional de Epidemiolog\u00eda, Prevenci\u00f3n y Control de Enfermedades. Bolet\u00edn mensual: Situaci\u00f3n epidemiol\u00f3gica del VIH\/SIDA en el Per\u00fa. Lima: Ministerio de Salud del Per\u00fa; 2018. Fecha de consulta: 26 de noviembre del 2025. Disponible en: https:\/\/www.dge.gob.pe\/portal\/docs\/vigilancia\/vih\/Boletin_2018\/diciembre.pdf"},{"key":"165056","unstructured":"Ministerio de Salud del Per\u00fa. Per\u00fa es el primer pa\u00eds de la regi\u00f3n que evaluar\u00e1 la resistencia del virus del VIH\/SIDA. Fecha de consulta: 26 de noviembre del 2025. Disponible en: https:\/\/www.gob.pe\/institucion\/minsa\/noticias\/39799-peru-es-el-primer-pais-de-la-regionque-evaluara-la-resistencia-del-virus-del-vih-sida"},{"key":"165057","doi-asserted-by":"crossref","unstructured":"Yabar CA, Vilcarino GF, Espetia S, Yaya MG, Salinas G, Garc\u00eda-Fern\u00e1ndez L, et al. Transmitted resistance in HIV-1 of patients from nine departments of Peru. Rev Peru Med Exp Salud Publica. 2021;38:77-82. https:\/\/doi.org\/10.17843\/rpmesp.2021.381.5527","DOI":"10.17843\/rpmesp.2021.381.5527"},{"key":"165058","unstructured":"Yabar CA, Vilcarino G, Yaya M, Espetia S, Acu\u00f1a M, Mamani E, et al. Multiple resistance and unusual mutations from HIV-1 infecting Peruvian patients with highly active antiretroviral therapy. HIV AIDS Res J. 2018;1:7922."},{"key":"165059","doi-asserted-by":"crossref","unstructured":"Yabar CA, Vilcarino GF, Espetia S, Lujan F, V\u00e1squez-Dom\u00ednguez A, Yaya M, et al. Social, epidemiological, and virological characteristics from Peruvian subjects living with HIV-1\/ AIDS with different sexual risk behavior. AIDS Res Hum Retroviruses. 2022;38:288-99. https:\/\/doi.org\/10.1089\/AID.2021.0067","DOI":"10.1089\/aid.2021.0067"},{"key":"165060","doi-asserted-by":"crossref","unstructured":"Yabar CA, Acu\u00f1a M, Gazzo C, Salinas G, C\u00e1rdenas F, Valverde A, et al. New subtypes and genetic recombination in HIV type 1-infecting patients with highly active antiretroviral therapy in Peru (2008-2010). AIDS Res Hum Retroviruses. 2012;28:1712-22. https:\/\/doi.org\/10.1089\/AID.2012.0040","DOI":"10.1089\/aid.2012.0040"},{"key":"165061","doi-asserted-by":"crossref","unstructured":"\u00c1vila MM, Pando MA, Carrion G, Peralta LM, Salomon H, Carrillo MG, et al. Two HIV-1 epidemics in Argentina: different genetic subtypes associated with different risk groups. J Acquir Immune Defic Syndr. 2002;29:422-6. https:\/\/doi.org\/10.1097\/00126334-200204010-00015","DOI":"10.1097\/00042560-200204010-00015"},{"key":"165062","doi-asserted-by":"crossref","unstructured":"Vrancken B, Baele G, Vandamme AM, van Laethem K, Suchard MA, Lemey P. Disentangling the impact of within-host evolution and transmission dynamics on the tempo of HIV-1 evolution. AIDS Lond Engl. 2015;29:1549-56. https:\/\/doi.org\/10.1097\/QAD.0000000000000731","DOI":"10.1097\/QAD.0000000000000731"},{"key":"165063","unstructured":"Y\u00e1bar VC, Salvatierra FJ, Quijano GE. Variabilidad del gen de la envoltura del VIH-1 en tres grupos humanos con diferentes conductas sexuales de riesgo para adquirir ITS-VIH. Rev Peru Med Exp Salud P\u00fablica. 2007;24:202-10."},{"key":"165064","doi-asserted-by":"crossref","unstructured":"Pingarilho M, Pimentel V, Miranda MNS, Silva AR, Diniz A, Ascen\u00e7\u00e3o BB, et al. HIV-1-transmitted drug resistance and transmission clusters in newly diagnosed patients in Portugal between 2014 and 2019. Front Microbiol. 2022;13:823208. https:\/\/doi.org\/10.3389\/fmicb.2022.823208","DOI":"10.3389\/fmicb.2022.823208"},{"key":"165065","doi-asserted-by":"crossref","unstructured":"Frentz D, van de Vijver D, Abecasis A, Albert J, Hamouda O, J\u00f8rgensen L, et al. Patterns of transmitted HIV drug resistance in Europe vary by risk group. PloS One. 2014;9:e94495. https:\/\/doi.org\/10.1371\/journal.pone.0094495","DOI":"10.1371\/journal.pone.0094495"},{"key":"165066","doi-asserted-by":"crossref","unstructured":"Gorbach PM, Drumright LN, Javanbakht M, Pond SL, Woelk CH, Daar ES, et al. Antiretroviral drug resistance and risk behavior among recently HIV-infected men who have sex with men. J Acquir Immune Defic Syndr. 2008;47:639-43. https:\/\/doi.org\/10.1097\/QAI.0b013e3181684c3d","DOI":"10.1097\/QAI.0b013e3181684c3d"},{"key":"165067","doi-asserted-by":"crossref","unstructured":"Kozal MJ, Amico KR, Chiarella J, Cornman D, Fisher W, Fisher J, et al. HIV drug resistance and HIV transmission risk behaviors among active injection drug users. J Acquir Immune Defic Syndr. 2005;40:106-9. https:\/\/doi.org\/10.1097\/01.qai.0000159666.95455.d2","DOI":"10.1097\/01.qai.0000159666.95455.d2"},{"key":"165068","doi-asserted-by":"crossref","unstructured":"Lau KA, Wong JJL. Current trends of HIV recombination worldwide. Infect Dis Rep. 2013;5(Suppl 1):e4. https:\/\/doi.org\/10.4081\/idr.2013.s1.e4","DOI":"10.4081\/idr.2013.s1.e4"},{"key":"165069","doi-asserted-by":"crossref","unstructured":"Rambaut A, Posada D, Crandall KA, Holmes EC. The causes and consequences of HIV evolution. Nat Rev Genet. 2004;5:52-61. https:\/\/doi.org\/10.1038\/nrg1246","DOI":"10.1038\/nrg1246"},{"key":"165070","unstructured":"Tebit DM, Nankya I, Arts EJ, Gao Y. HIV diversity, recombination and disease progression: how does fitness \"fit\" into the puzzle? AIDS Rev. 2007;9:75-87."},{"key":"165071","doi-asserted-by":"crossref","unstructured":"Gore DJ, Schueler K, Ramani S, Uvin A, Phillips G, McNulty M, et al. HIV response interventions that integrate hiv molecular cluster and social network analysis:A systematic review. AIDS Behav. 2022;26:1750-92. https:\/\/doi.org\/10.1007\/s10461-021-03525-0","DOI":"10.1007\/s10461-021-03525-0"},{"key":"165072","doi-asserted-by":"crossref","unstructured":"Long JE, Tordoff DM, Reisner SL, Dasgupta S, Mayer KH, Mullins JI, et al. HIV transmisi\u00f3n patterns among transgender women, their cisgender male partners, and cisgender MSM in Lima, Peru: A molecular epidemiologic and phylodynamic analysis. Lancet Reg Health Am. 2022;6:100121. https:\/\/doi.org\/10.1016\/j.lana.2021.100121","DOI":"10.1016\/j.lana.2021.100121"},{"key":"165073","doi-asserted-by":"crossref","unstructured":"Noiman A, Macalino G, Won SH, Byrne M, Deiss R, Haw NJ, et al. Sexual risk behaviors associated with sexually transmitted infections in a US military population living with HIV after the repeal of \u00abDon\u2019t Ask, Don\u2019t Tell\u00bb. AIDS Patient Care STDS. 2020;34:523-33. https:\/\/doi.org\/10.1089\/apc.2020.0095","DOI":"10.1089\/apc.2020.0095"},{"key":"165074","doi-asserted-by":"crossref","unstructured":"Evans MW, Borrero S, Yabes J, Rosenfeld EA. Sexual behaviors and sexually transmitted infections among male veterans and nonveterans. Am J Mens Health. 2017;11:791-800. https:\/\/doi.org\/10.1177\/1557988317698615","DOI":"10.1177\/1557988317698615"},{"key":"165075","doi-asserted-by":"crossref","unstructured":"Apolaya-Segura M, C\u00e1rcamo-Cavagnaro C. Influencia del servicio militar voluntario sobre el comportamiento sexual de una poblaci\u00f3n de j\u00f3venes. Rev Peru Med Exp Salud P\u00fablica. 2013;30:386-92.","DOI":"10.17843\/rpmesp.2013.303.272"},{"key":"165076","doi-asserted-by":"crossref","unstructured":"De la Cruz Ku G, Rojas Contreras C, Chambergo-Michilot D, Torres-Roman JS, Pr\u00edncipe-Meneses FS, Rioja Torres F, et al. HIV therapy adherence and outcomes in Peruvian military personnel over a 30-year period. Electron J Gen Med. 2023;20:em443. https:\/\/doi.org\/10.29333\/ejgm\/12776","DOI":"10.29333\/ejgm\/12776"},{"key":"165077","doi-asserted-by":"crossref","unstructured":"Garc\u00eda-Fern\u00e1ndez L, Novoa R, Huam\u00e1n B, Benites C. Continuo de la atenci\u00f3n de personas que viven con VIH y brechas para el logro de las metas 90-90-90 en Per\u00fa. Rev Peru Med Exp Salud Publica. 2018;35:385-93.","DOI":"10.17843\/rpmesp.2018.353.3853"},{"key":"165078","doi-asserted-by":"crossref","unstructured":"Cho YK, Kim JE, Foley BT. High prevalence of non-B HIV-1 subtypes in overseas sailors and prostitutes in Korea. AIDS Res Hum Retroviruses. 2018;34:347-53. https:\/\/doi.org\/10.1089\/AID.2017.0238","DOI":"10.1089\/aid.2017.0238"},{"key":"165079","doi-asserted-by":"crossref","unstructured":"Singer DE, Bautista CT, O\u2019Connell RJ, Sanders-Buell E, Agan BK, Kijak GH, et al. HIV infection among U.S. Army and Air Force military personnel: Sociodemographic and genotyping analysis. AIDS Res Hum Retroviruses. 2010;26:889-94. https:\/\/doi.org\/10.1089\/aid.2009.0289","DOI":"10.1089\/aid.2009.0289"},{"key":"165080","doi-asserted-by":"crossref","unstructured":"Tovanabutra S, Brodine SK, Mascola JR, Sankale JL, Sanders-Buell E, Kim B, et al. Characterization of complete HIV type 1 genomes from non-B subtype infections in U.S. military personnel. AIDS Res Hum Retroviruses. 2005;21:424-9. https:\/\/doi.org\/10.1089\/aid.2005.21.424","DOI":"10.1089\/aid.2005.21.424"},{"key":"165081","unstructured":"Yabar VC, Chavez HP, Varas HZ, Rodriguez BR. Identificaci\u00f3n molecular de mutaciones puntuales relacionadas con resistencia a drogas en VIH-1 de pacientes peruanos. Rev Peru Med Exp Salud P\u00fablica. 2006;23:149-57."},{"key":"165082","doi-asserted-by":"crossref","unstructured":"Yabar CA, Salvatierra J, Quijano E. Polymorphism, recombination, and mutations in HIV type 1 gag-infecting Peruvian male sex workers. AIDS Res Hum Retroviruses. 2008;24:1405-13. https:\/\/doi.org\/10.1089\/aid.2008.0130","DOI":"10.1089\/aid.2008.0130"},{"key":"165083","doi-asserted-by":"crossref","unstructured":"Tajima F. Statistical analysis of DNA polymorphism. Idengaku Zasshi. 1993;68:567-95. https:\/\/doi.org\/10.1266\/jjg.68.567","DOI":"10.1266\/ggs.68.567"},{"key":"165084","doi-asserted-by":"crossref","unstructured":"Boyer CB, Gaydos CA, Geller AB, Garges EC, Vermund SH. Sexually transmitted infections in the u.s. military: a sexual health paradigm to address risk behaviors, unintended pregnancy, alcohol use, and sexual trauma. Mil Med. 2022;187:140-3. https:\/\/doi.org\/10.1093\/milmed\/usab407","DOI":"10.1093\/milmed\/usab407"},{"key":"165085","doi-asserted-by":"crossref","unstructured":"Poudel KC, Poudel-Tandukar K, Yasuoka J, Jimba M. HIV superinfection: another reason to avoid serosorting practice. Lancet Lond Engl. 2007;370:23. https:\/\/doi.org\/10.1016\/S0140-6736(07)61033-2","DOI":"10.1016\/S0140-6736(07)61033-2"},{"key":"165086","doi-asserted-by":"crossref","unstructured":"Allen TM, Altfeld M. HIV-1 superinfection. J Allergy Clin Immunol. 2003;112:829-35. https:\/\/doi.org\/10.1016\/j.jaci.2003.08.037","DOI":"10.1016\/j.jaci.2003.08.037"},{"key":"165087","doi-asserted-by":"crossref","unstructured":"Cornelissen M, Pasternak AO, Grijsen ML, Zorgdrager F, Bakker M, Blom P, et al. HIV-1 dual infection is associated with faster CD4+ T-cell decline in a cohort of men with primary HIV infection. Clin Infect Dis. 2012;54:539-47. https:\/\/doi.org\/10.1093\/cid\/cir849","DOI":"10.1093\/cid\/cir849"},{"key":"165088","doi-asserted-by":"crossref","unstructured":"Chakraborty B, Kiser P, Rangel HR, Weber J, Mirza M, Marotta ML, et al. Can HIV-1 superinfection compromise antiretroviral therapy? AIDS Lond Engl. 2004;18:132-4. https:\/\/doi.org\/10.1097\/00002030-200401020-00019","DOI":"10.1097\/00002030-200401020-00019"},{"key":"165089","doi-asserted-by":"crossref","unstructured":"Manigart O, Courgnaud V, Sanou O, Val\u00e9a D, Nagot N, Meda N, et al. HIV-1 superinfections in a cohort of commercial sex workers in Burkina Faso as assessed by an autologous heteroduplex mobility procedure. AIDS Lond Engl. 2004;18:1645-51. https:\/\/doi.org\/10.1097\/01.aids.0000131333.30548.db","DOI":"10.1097\/01.aids.0000131333.30548.db"},{"key":"165090","doi-asserted-by":"crossref","unstructured":"Luan H, Han X, Yu X, An M, Zhang H, Zhao B, et al. dual infection contributes to rapid disease progression in men who have sex with men in China. J Acquir Immune Defic Syndr. 2017;75:480-7. https:\/\/doi.org\/10.1097\/QAI.0000000000001420","DOI":"10.1097\/QAI.0000000000001420"},{"key":"165091","doi-asserted-by":"crossref","unstructured":"Cornelissen M, Jurriaans S, Kozaczynska K, Prins JM, Hamidjaja RA, Zorgdrager F, et al. Routine HIV-1 genotyping as a tool to identify dual infections. AIDS Lond Engl. 2007;21:807-11. https:\/\/doi.org\/10.1097\/QAD.0b013e3280f3c08a","DOI":"10.1097\/QAD.0b013e3280f3c08a"},{"key":"165092","doi-asserted-by":"crossref","unstructured":"Russell KL, Carcamo C, Watts DM, Sanchez J, Gotuzzo E, Euler A, et al. Emerging genetic diversity of HIV-1 in South America. AIDS Lond Engl. 2000;14:1785-91. https:\/\/doi.org\/10.1097\/00002030-200008180-00014","DOI":"10.1097\/00002030-200008180-00014"},{"key":"165093","doi-asserted-by":"crossref","unstructured":"Delatorre EO, Bello G, Eyer-Silva WA, Chequer-Fernandez SL, Morgado MG, Couto-Fernandez JC. Evidence of multiple introductions and autochthonous transmission of the HIV type 1 CRF02_AG clade in Brazil. AIDS Res Hum Retroviruses. 2012;28:1369-72. https:\/\/doi.org\/10.1089\/AID.2011.0381","DOI":"10.1089\/aid.2011.0381"},{"key":"165094","doi-asserted-by":"crossref","unstructured":"Carrion G, Hierholzer J, Montano S, Alava A, Perez J, Guevara A, et al. Circulating recombinant form CRF02_AG in South America. AIDS Res Hum Retroviruses. 2003;19:329-32. https:\/\/doi.org\/10.1089\/088922203764969537","DOI":"10.1089\/088922203764969537"},{"key":"165095","doi-asserted-by":"crossref","unstructured":"Rangel HR, Garzaro D, Guti\u00e9rrez CR, V\u00e1squez L, Guillen G, Torres JR, et al. HIV diversity in Venezuela: predominance of HIV type 1 subtype B and genomic characterization of non-B variants. AIDS Res Hum Retroviruses. 2009;25:347-50. https:\/\/doi.org\/10.1089\/aid.2008.0241","DOI":"10.1089\/aid.2008.0241"},{"key":"165096","doi-asserted-by":"crossref","unstructured":"Fern\u00e1ndez MF, Golemba MD, Terrones C, Paradiso P, Nassif JC, Bologna R, et al. Short communication: Emergence of novel A\/G recombinant HIV-1 strains in Argentina. AIDS Res Hum Retroviruses. 2015;31:293-7. https:\/\/doi.org\/10.1089\/AID.2014.0196","DOI":"10.1089\/aid.2014.0196"},{"key":"165097","doi-asserted-by":"crossref","unstructured":"Castro-Nallar E, P\u00e9rez-Losada M, Burton GF, Crandall KA. The evolution of HIV: inferences using phylogenetics. Mol Phylogenet Evol. 2012;62:777-92. https:\/\/doi.org\/10.1016\/j.ympev.2011.11.019","DOI":"10.1016\/j.ympev.2011.11.019"},{"key":"165098","doi-asserted-by":"crossref","unstructured":"Fun A, Leitner T, Vandekerckhove L, D\u00e4umer M, Thielen A, Buchholz B, et al. Impact of the HIV-1 genetic background and HIV-1 population size on the evolution of raltegravir resistance. Retrovirology. 2018;15:1. https:\/\/doi.org\/10.1186\/s12977-017-0384-z","DOI":"10.1186\/s12977-017-0384-z"},{"key":"165099","doi-asserted-by":"crossref","unstructured":"Kearney MF, Spindler J, Shao W, Yu S, Anderson EM, O\u2019Shea A, et al. Lack of detectable HIV-1 molecular evolution during suppressive antiretroviral therapy. PLOS Pathog. 2014;10:e1004010. https:\/\/doi.org\/10.1371\/journal.ppat.1004010","DOI":"10.1371\/journal.ppat.1004010"},{"key":"165100","doi-asserted-by":"crossref","unstructured":"Abdi B, Nguyen T, Brouillet S, Desire N, Sayon S, Wirden M, et al. No HIV-1 molecular evolution on long-term antiretroviral therapy initiated during primary HIV-1 infection. AIDS Lond Engl. 2020;34:1745-53. https:\/\/doi.org\/10.1097\/QAD.0000000000002629","DOI":"10.1097\/QAD.0000000000002629"},{"key":"165101","doi-asserted-by":"crossref","unstructured":"Baheti G, King JR, Acosta EP, Fletcher CV. Age-related differences in plasma and intracellular tenofovir concentrations in HIV-1-infected children, adolescents and adults. AIDS Lond Engl. 2013;27:221-5. https:\/\/doi.org\/10.1097\/QAD.0b013e32835a9a2d","DOI":"10.1097\/QAD.0b013e32835a9a2d"},{"key":"165102","doi-asserted-by":"crossref","unstructured":"Schoen JC, Erlandson KM, Anderson PL. Clinical pharmacokinetics of antiretroviral drugs in older persons. Expert Opin Drug Metab Toxicol. 2013;9:573\u201388. https:\/\/doi.org\/10.1517\/17425255.2013.781153","DOI":"10.1517\/17425255.2013.781153"},{"key":"165103","doi-asserted-by":"crossref","unstructured":"Stader F, Courlet P, Kinvig H, Battegay M, Decosterd LA, Penny MA, et al. Effect of ageing on antiretroviral drug pharmacokinetics using clinical data combined with modelling and simulation. Br J Clin Pharmacol. 2021;87:458-70. https:\/\/doi.org\/10.1111\/bcp.14402","DOI":"10.1111\/bcp.14402"},{"key":"165104","doi-asserted-by":"crossref","unstructured":"De Sousa Mendes M, Chetty M. Are standard doses of renally-excreted antiretrovirals in older patients appropriate? A PBPK study comparing exposures in the elderly population with those in renal impairment. Drugs R D. 2019;19:339-50. https:\/\/doi.org\/10.1007\/s40268-019-00285-0","DOI":"10.1007\/s40268-019-00285-0"},{"key":"165105","doi-asserted-by":"crossref","unstructured":"Kearney BP, Yale K, Shah J, Zhong L, Flaherty JF. Pharmacokinetics and dosing recommendations of tenofovir disoproxil fumarate in hepatic or renal impairment. Clin Pharmacokinet. 2006;45:11152. https:\/\/doi.org\/10.2165\/00003088-200645110-00005","DOI":"10.2165\/00003088-200645110-00005"},{"key":"165106","doi-asserted-by":"crossref","unstructured":"Brooks K, Omondi FH, Liang RH, Sudderuddin H, Jones BR, Joy JB, et al. Proviral turnover during untreated hiv infection is dynamic and variable between hosts, impacting reservoir composition on ART. Front Microbiol. 2021;12:719153. https:\/\/doi.org\/10.3389\/fmicb.2021.719153","DOI":"10.3389\/fmicb.2021.719153"},{"key":"165107","doi-asserted-by":"crossref","unstructured":"Gantner P, Morand-Joubert L, Sueur C, Raffi F, Fagard C, Lascoux-Combe C, et al. Drug resistance and tropism as markers of the dynamics of HIV-1 DNA quasispecies in blood cells of heavily pretreated patients who achieved sustained virological suppression. J Antimicrob Chemother. 2016;71:751-61. https:\/\/doi.org\/10.1093\/jac\/dkv395","DOI":"10.1093\/jac\/dkv395"},{"key":"165108","unstructured":"Matos AF, Ju\u00e1rez LH. Caracterizaci\u00f3n epidemiol\u00f3gica, cl\u00ednica y laboratorial de pacientes con infecci\u00f3n por el VIH\/SIDA en tratamiento antirretroviral con falla virol\u00f3gica y exploraci\u00f3n de factores asociados en un hospital nacional de III nivel-Lima, Per\u00fa 2010-2017 (tesis). Lima: Universidad Peruana Cayetano Heredia; 2018. Fecha de consulta: 26 de noviembre del 2025. Disponible en: https:\/\/repositorio.upch.edu.pe\/entities\/publication\/670e5588-2d9f-44e6-a6ae-caa28c5366eb"},{"key":"165109","unstructured":"Romero SRM, Ortiz LM. Perfil gen\u00f3mico de resistencia a medicamentos antirretrovirales en pacientes infectados por el VIH\/SIDA con falla virol\u00f3gica en un hospital de nivel III-Lima, Per\u00fa; 2017-2023 (tesis). Lima: Universidad Peruana Cayetano Heredia; 2024. Fecha de consulta: 26 de noviembre del 2025. Disponible en: https:\/\/repositorio.upch.edu.pe\/entities\/publication\/eb47c15c-7317-4683-9008-353dea544c18"},{"key":"165110","doi-asserted-by":"crossref","unstructured":"Barrera-Espinoza RW, G\u00f3mez-Gonzales WE, Gir\u00f3n-Vargas A, Arana-Escobar M, Nieva-Villegas LM, Gamarra-Bustillos C, et al. Factores asociados a la no adherencia al tratamiento antirretroviral en personas con VIH\/SIDA. Horiz Med (Lima). 2021;21:e1498. https:\/\/doi.org\/10.24265\/horizmed.2021.v21n4.09","DOI":"10.24265\/horizmed.2021.v21n4.09"},{"key":"165111","doi-asserted-by":"crossref","unstructured":"Stader F, Courlet P, Decosterd LA, Battegay M, Marzolini C. Physiologically-based pharmacokinetic modeling combined with Swiss HIV Cohort Study data supports no dose adjustment of bictegravir in elderly individuals living with HIV. Clin Pharmacol Ther. 2021;109:1025-9. https:\/\/doi.org\/10.1002\/cpt.2178","DOI":"10.1002\/cpt.2178"},{"key":"165112","doi-asserted-by":"crossref","unstructured":"Toledo T, Castro T, Oliveira VG, Veloso VG, Grinsztejn B, Cardoso SW, et al. Pharmacokinetics of antiretroviral drugs in older people living with HIV: a systematic review. Clin Pharmacokinet. 2023;62:1219-30. https:\/\/doi.org\/10.1007\/s40262-023-01291-x","DOI":"10.1007\/s40262-023-01291-x"},{"key":"165113","doi-asserted-by":"crossref","unstructured":"Coulter JR, Geretti AM, Dunn DT, et al. Effects of age on antiretroviral plasma drug concentration in HIV-infected subjects undergoing routine therapeutic drug monitoring. J Antimicrob Chemother. 2013;68:1354-60. https:\/\/doi.org\/10.1093\/jac\/dkt038","DOI":"10.1093\/jac\/dkt038"}],"container-title":["Biom\u00e9dica"],"original-title":[],"link":[{"URL":"https:\/\/revistabiomedica.org\/index.php\/biomedica\/article\/download\/7970\/5921","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/revistabiomedica.org\/index.php\/biomedica\/article\/download\/7970\/5921","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T03:20:53Z","timestamp":1783048853000},"score":1,"resource":{"primary":{"URL":"https:\/\/revistabiomedica.org\/index.php\/biomedica\/article\/view\/7970"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,1]]},"references-count":63,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,6,1]]}},"URL":"https:\/\/doi.org\/10.7705\/biomedica.7970","relation":{},"ISSN":["2590-7379","0120-4157"],"issn-type":[{"value":"2590-7379","type":"electronic"},{"value":"0120-4157","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6,1]]},"assertion":[{"value":"2026-06-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}},{"value":"Yes","order":0,"name":"peer_reviewed","label":"Peer Reviewed","group":{"name":"peer_review","label":"Peer Review"}},{"value":"Instituto Nacional de Salud","name":"publisher","label":"This article is maintained by"},{"value":"Biomedica","name":"journaltitle","label":"Journal Title"},{"value":"Art\u00edculos originales","name":"content_type","label":"Content Type"}]}}